



0230
1-3
1600
#3
DVT
4-38-01

CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231			
Typed or Printed Name	Steven F. Goldstein		
Signature		Date	2/28/01
TRANSMITTAL FORM (to be used for all correspondence after initial filing)	Attorney Docket	IRVN-0007CON	
	First Named Inventor	Gatanaga et al.	
	Application Number	09/712,813	
	Filing Date	November 13, 2000	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
	Title: <i>Factors Affecting Tumor Necrosis Factor Receptor Releasing Enzyme Activity</i>		

ENCLOSURES (check all that apply)		
<input type="checkbox"/> Fee Transmittal Form	<input type="checkbox"/> Issue Fee Transmittal (with copy of PTOL-85B)	<input type="checkbox"/> Request for Refund
<input type="checkbox"/> Amendment/Response <input type="checkbox"/> After Final <input type="checkbox"/> Affidavits/declaration(s)	<input type="checkbox"/> Formal Drawing(s)	<input type="checkbox"/> After Allowance Communication to Group
<input type="checkbox"/> Extension of Time Request	<input type="checkbox"/> Licensing-related Papers	<input type="checkbox"/> Appeal Communication to Board of Appeals and Interferences
<input type="checkbox"/> Express Abandonment Request	<input type="checkbox"/> Petition Routing Slip and Accompanying Petition	<input type="checkbox"/> Appeal Communication to Group (Appeal Notice, Brief, Reply Brief)
<input checked="" type="checkbox"/> Information Disclosure Statement, 1449 and 16 references	<input type="checkbox"/> To Convert a Provisional Application	<input type="checkbox"/> Proprietary Information
<input type="checkbox"/> Certified Copy of Priority Document(s)	<input type="checkbox"/> Power of Attorney <input type="checkbox"/> Revocation <input type="checkbox"/> Associate	<input type="checkbox"/> Status Letter
<input type="checkbox"/> Response to Missing Parts/ Incomplete Application	<input type="checkbox"/> Change of Correspondence Address	<input checked="" type="checkbox"/> Additional Enclosure(s) (please identify below): <u>Return Postcard</u>
<input type="checkbox"/> Response to Missing Parts under 37 CFR 1.52 or 1.53 (with copy of Notice to File Missing Parts)	<input type="checkbox"/> Terminal Disclaimer	
	<input type="checkbox"/> Small Entity Statement	

SIGNATURE OF APPLICANT, ATTORNEY, OR AGENT			
Individual Name	Carol L. Francis	Registration No.	36,513
Firm Name	BOZICEVIC, FIELD & FRANCIS LLP		
Signature			
Date	February 28, 2001		

RECEIVED

APR 03 2001

TECH CENTER 1600/2900



CERTIFICATE OF MAILING			
I hereby certify that this correspondence is being deposited with the United States Postal Service as first class mail in an envelope addressed to: Commissioner for Patents, Washington, D.C. 20231 on this date.			
Typed or Printed Name	Steven F. Goldstein		
Signature		Date	2/28/01
INFORMATION DISCLOSURE STATEMENT Address to: Commissioner for Patents Washington, D.C. 20231	Attorney Docket	IRVN-0007CON	
	First Named Inventor	Gatanaga et al.	
	Application Number	09/712,813	
	Filing Date	November 13, 2000	
	Group Art Unit	Unassigned	
	Examiner Name	Unassigned	
	Title	Factors Affecting Tumor Necrosis Factor Receptor Releasing Enzyme Activity	

APR 03 2001

RECEIVED

Sir:

This is an Information Disclosure Statement submitted for the Examiner's consideration. A Form PTO-1449 listing the references and copies of the cited references accompany this paper. Applicants would appreciate the Examiner's initialing and returning the form to indicate that the references have been reviewed and made of record.

This Information Disclosure Statement is not intended as a representation that a search has been made, that additional information material to the examination of this application does not exist, or that any one of the above references constitutes prior art to the present application within the meaning of 35 U.S.C. §102.

As applicants have not yet received a first Action on the merits, no fee is believed to be required for filing this Disclosure Statement. If, however, the PTO finds that for some reason a fee is due, our Deposit Account No. 50-0815 may be charged therefor.

Respectfully submitted,
BOZICEVIC, FIELD & FRANCIS LLP

Date:

By:

Carol L. Francis
Registration No. 36,513

BOZICEVIC, FIELD & FRANCIS LLP
200 Middlefield Road, Suite 200
Menlo Park, CA 94025
Telephone: (650) 327-3400
Facsimile: (650) 327-3231
F:\FORMS\Word 2K forms\IDS - before 1st OA.doc